Alzheimer'
Conditions
Interventions
Administration of rivastigmine patch to untreated Alzheimer-type dementia patients will be started.
Patients currently receiving other cholinesterase inhibitors (donepezil, galantamine) will switch to
Sponsors
Second Department of Internal Medicine, Faculty of Medical Scieces, University of Fukui
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Targets and planned number of studies A total of 50 Alzheimer's dementia patients living in Fukui Prefecture (2) Place of implementation Fukui University Hospital Target patients who meet all of the following criteria: 1 Alzheimer-type dementia patients diagnosed as mild and moderate 2 Patients aged 50 to 85 at the time of obtaining consent 3 Patients who can be accompanied by a caregiver at the time of examination 4 Patients (or legal representatives) who can obtain written informed consent to participate in this study 5. Patients who were informed by carers regarding their participation in this study.
Exclusion criteria
Exclusion criteria: Patients who have any of the following are excluded. 1. Patients who participated in other clinical trials within 4 months 2. Other patients who the investigator determined to be unsuitable for study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Appetite Questionnaire (JSNAQ) (at the start of the test, 3, 6 and 12 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| MMSE-J (cognitive function evaluation) (at the start of the test, 3, 6 and 12 months) ADAS-Jcog (cognitive function evaluation) (at the start of the study, 3, 6, and 12 months) | — |
Countries
Japan
Contacts
Public ContactTadanori Hamano
University of Fukui Faculty of Medical Sciecnes, Second Department of Internal Medicine, University of Fukui
Outcome results
None listed